文献速递血液净化与透析急性肾损伤慢性肾脏病

左心室辅助装置、肾病与透析

Left Ventricular Assist Devices, Kidney Disease, and Dialysis.
PubMed 文献 · Am J Kidney Dis · 2017-12-14

本综述概述了左心室辅助装置(LVAD)的原理与适应证,并讨论了LVAD植入后肾功能变化、透析方式选择及血管通路等问题。综述指出,肾小球滤过率长期低于30mL/min/1.73m2者通常不适合接受目的地治疗LVAD,但部分晚期慢性肾脏病患者可考虑作为心脏或心肾移植的桥接;LVAD植入后需透析的急性肾损伤患者死亡率高。

要点

  • LVAD可改善晚期心衰患者生存,但合并肾病者管理数据有限。
  • GFR长期<30mL/min/1.73m2者通常不适合目的地LVAD,可考虑移植桥接。
  • LVAD后需透析的急性肾损伤患者死亡率高,透析方式可选血透、腹透或家庭血透。

核心结论

  • LVAD改善晚期心衰生存,但合并肾病患者的最佳管理证据有限。
  • GFR长期<30mL/min/1.73m2者通常不适合目的地LVAD,部分可考虑移植桥接。
  • LVAD后需透析的急性肾损伤患者死亡率高。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • LVAD植入后短期肾功能可能改善,尤其存在心肾生理时;长期数据有限。
  • GFR长期<30mL/min/1.73m2者(含维持性透析)通常不适合目的地LVAD。
  • 部分晚期慢性肾脏病患者可考虑LVAD作为心脏或心肾移植桥接。
  • LVAD后发生急性肾损伤需透析者死亡率高。
  • 每周三次血透是最常用模式,腹透和家庭血透为可选方案;腹透可能与更低血流感染风险和更少血流动力学波动相关。

关键数值与推荐

  • GFR长期<30mL/min/1.73m2(含维持性透析)通常不适合目的地LVAD。
  • 部分晚期慢性肾脏病患者可考虑LVAD作为心脏或心肾移植桥接。
  • LVAD后需透析的急性肾损伤患者死亡率高。
  • 每周三次血透是最常用模式,腹透和家庭血透为可选方案。

临床怎么用

  • 评估LVAD候选者时需关注GFR长期<30mL/min/1.73m2通常不适合目的地治疗。
  • LVAD后需透析者优先考虑腹透或家庭血透以减少血流感染和血流动力学波动。
  • 血透患者可成功使用动静脉内瘘作为血管通路。

局限性

  • LVAD合并肾病患者管理数据稀疏。
  • LVAD后长期肾功能数据有限。
  • 贫血管理和血透方案优化等问题尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Left ventricular assist devices (LVADs) improve survival in patients with advanced heart failure. As LVAD use increases, so do the number of patients with LVADs who also have kidney disease. However, there are only sparse data on how best to care for these patients. This review provides an overview of LVAD principles and indications, including blood pressure assessment and criteria for receipt of both destination and bridge to transplantation LVADs. Following LVAD implantation, kidney function may improve in the short term, particularly if cardiorenal physiology was present; in the longer term, data remain limited. Individuals with glomerular filtration rates chronically < 30mL/min/1.73m2, including those treated with maintenance dialysis, are generally ineligible for destination LVADs. However, select patients with advanced chronic kidney disease can be considered for LVADs as a bridge to heart or heart-kidney transplantation. Patients who develop acute kidney injury and require dialysis following LVAD implantation have high mortality rates. Although thrice-weekly hemodialysis is the most common modality for patients with LVADs, peritoneal dialysis and home hemodialysis are additional options. Peritoneal dialysis in particular may be associated with lower risk for bloodstream infection and fewer hemodynamic shifts. For those treated with hemodialysis, arteriovenous fistulas can successfully be used for vascular access. Many questions remain, including optimal anemia management and refinement of hemodialysis protocols for patients with an LVAD, and further research is needed in this field.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Roehm B, Vest AR, Weiner DE, et al. Left Ventricular Assist Devices, Kidney Disease, and Dialysis. Am J Kidney Dis. 2017. PMID: 29249390. doi:10.1053/j.ajkd.2017.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。